RNAi技術與全球市場

RNAi Technologies and Global Markets

出版日期: 2024年06月25日 | 出版商:

BCC Research | 英文 118 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球 RNAi 技術市場規模預計將從 2023 年的 21 億美元增加到 2029 年的 48 億美元，預測期內複合年成長率為 14.8%。

治療產業預計將從 2023 年的 16 億美元成長到 2029 年的 39 億美元，複合年成長率為 16.2%。此外，工具和試劑領域預計將從2023年的5.029億美元成長到2029年的8.828億美元，複合年成長率為9.9%。

本報告調查了全球RNAi技術市場，並提供了市場概況、市場影響因素和市場機會分析、新興技術和技術發展趨勢、市場規模趨勢和預測、各個細分市場和地區的詳細分析，總結了競爭格局，主要企業簡介等

Report Scope

The scope of this study encompasses an investigation of the ribonucleic acid interference (RNAi) technology market. BCC Research analyzes RNAi technology based on technology type: tools and reagents, diagnostics, therapeutics, and agriculture. BCC Research determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next six years. The report provides a detailed analysis of the market's drivers, restraints, challenges, and opportunities. It includes company profiles of key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides detailed information on emerging technologies and new developments in the market; examines the regulatory landscape; provides a patent and pipeline analysis; and discusses ESG developments, the investment outlook, and deals within the market.

Report Includes

26 data tables and 53 additional tables
An overview of the global market for RNAi technologies
Analysis of global market trends, featuring revenue data for 2021- 2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
Evaluation of the current market's size and revenue growth prospects, along with a market share analysis by type, therapeutic area, delivery method, and region
A look at innovations, technological advances, and recent product launches in the RNAi market
Analysis of the industry's regulatory framework and policies
A discussion of ESG challenges and ESG practices in the RNAi technologies industry
An analysis of the key companies' market shares, proprietary technologies, and strategic alliances
Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Novartis AG, Thermo Fisher Scientific Inc., and Revvity Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary

Chapter 2 Market Overview

Background: Genetic Material
RNA Interference Overview
RNA Interference: Mechanism of Action
Initiation Phase
Effector Phase
Small Interfering RNAs (siRNAs)
MicroRNAs (miRNAs)
Small Hairpin RNAs (shRNAs)

Chapter 3 Market Dynamics

Global Market Dynamics
Market Drivers
Increasing Prevalence of Chronic Disease
Increasing Approval of RNAi Products
Advancements in RNAi Delivery Systems
Increasing Strategic Initiatives
Convenient Dosing
Market Restraints
High Treatment Costs
Lack of Awareness
Market Opportunities
Expansion of Disease Targets
Combination Therapies
Untapped Genetic Targets

Chapter 4 Emerging Technologies and Developments

Therapeutics
Diagnostics
Circulating miRNA Diagnostics for Non-invasive Health Monitoring
Agriculture

Chapter 5 Pipeline Analysis

Chapter 6 Patent Analysis

Patent Analysis

Chapter 7 Market Segmentation Analysis

Segmentation Breakdown
Overview
Market Analysis by Technology
Therapeutics
RNAi Therapeutics Market, by Region
RNAi Therapeutics Market, by Therapeutic Area
RNAi Therapeutics Market, by Delivery Method
Diagnostics
Reagents and Tools
Agriculture
Geographic Breakdown
Market Analysis by Region
North America
Europe
Emerging Markets

Chapter 8 Competitive Intelligence

Strategic Initiatives
Competitive Analysis

Chapter 9 Sustainability in RNAi Technology Market: An ESG Perspective

Introduction to ESG
Sustainability in RNAi Technology Industry: An ESG Perspective
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study
Concluding Remarks from BCC

Chapter 10 Appendix

Methodology
Acronyms
Sources
Company Profiles
ALNYLAM PHARMACEUTICALS INC.
ARROWHEAD PHARMACEUTICALS INC.
ARBUTUS BIOPHARMA CORP.
BAYER AG
MERCK KGAA
NOVARTIS AG
NOVO NORDISK A/S
OLIX PHARMACEUTICALS INC.
QIAGEN
REVVITY INC.
SILENCE THERAPEUTICS
SIRNAOMICS
SYLENTIS S.A.
SWITCH THERAPEUTICS
THERMO FISHER SCIENTIFIC INC.

簡介目錄圖表

List of Tables

Summary Table : Global Market for RNAi Technology, by Technology Type, Through 2029
Table 1 : Projected Number of Adults 50 Years and Older with >=1 Chronic Condition in the U.S., 2020-2050
Table 2 : Cost Comparison of siRNA-approved Drugs and Alternative Therapies
Table 3 : List of Selected Pipeline Molecules
Table 4 : Selected Patents for RNAi Technology, Published in 2021
Table 5 : Selected Patents for RNAi Technology, Published in 2022
Table 6 : Selected Patents for RNAi Technology, Published in 2023
Table 7 : Selected Patents for RNAi Technology, Published January to April 2024
Table 8 : Global Market for RNAi Technology, by Technology Type, Through 2029
Table 9 : RNAi Approved Drugs List
Table 10 : Global Market for RNAi Therapeutics, by Region, Through 2029
Table 11 : Global Market for RNAi Therapeutics, by Therapeutic Area, Through 2029
Table 12 : Global Market for RNAi Therapeutics, by Delivery Method, Through 2029
Table 13 : miRNA-based Diagnostic Tools Available in Clinical Settings
Table 14 : Global Market for RNAi Diagnostics, by Region, Through 2029
Table 15 : Global Market for RNAi Reagents and Tools, by Type, Through 2029
Table 16 : Global Market for RNAi Reagents and Tools, by Region, Through 2029
Table 17 : Global Market for RNAi Research Tools and Constructs, by Region, Through 2029
Table 18 : Global Market for RNAi Reagents, by Region, Through 2029
Table 19 : Global Market for RNAi Agriculture, by Region, Through 2029
Table 20 : Global Market for RNAi Technology, by Region, Through 2029
Table 21 : Strategic Initiatives in Global RNAi Technology Market, 2020-2024
Table 22 : Global Rankings of Top RNAi Reagents and Tools Manufacturers, 2022
Table 23 : Key Focus Areas in ESG Metrices
Table 24 : Environmental Initiatives, by Various RNAi Technology Companies
Table 25 : ESG Rankings for Companies in the RNAi Technology Market, 2023
Table 26 : Alnylam's ESG initiatives
Table 27 : Glossary of Terms Used in This Report
Table 28 : Report Information Sources
Table 29 : Alnylam Pharmaceuticals Inc.: Company Snapshot
Table 30 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 31 : Alnylam Pharmaceuticals Inc.: Product Portfolio
Table 32 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2023
Table 33 : Arrowhead Pharmaceuticals Inc.: Company Snapshot
Table 34 : Arrowhead Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 35 : Arrowhead Pharmaceuticals Inc.: News/Key Developments, 2021-2024
Table 36 : Arbutus BioPharma Corp.: Company Snapshot
Table 37 : Arbutus Biopharma Corp.: Financial Performance, FY 2022 and 2023
Table 38 : Arbutus BioPharma Corp.: News/Key Developments, 2021-2023
Table 39 : Bayer AG: Company Snapshot
Table 40 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 41 : Bayer AG: Product Portfolio
Table 42 : Bayer AG: News/Key Developments, 2023
Table 43 : Merck KGaA: Company Snapshot
Table 44 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 45 : Merck KGaA.: Product Portfolio
Table 46 : Merck KGaA: News/Key Developments, 2021-2024
Table 47 : Novartis AG: Company Snapshot
Table 48 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 49 : Novartis AG: Product Portfolio
Table 50 : Novartis AG: News/Key Developments, 2020-2024
Table 51 : Novo Nordisk A/S: Company Snapshot
Table 52 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 53 : Novo Nordisk A/S: Product Portfolio
Table 54 : Novo Nordisk A/S: News/Key Developments, 2021-2023
Table 55 : OliX Pharmaceuticals Inc.: Company Snapshot
Table 56 : OliX Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 57 : OliX Pharmaceuticals Inc.: News/Key Developments, 2019-2023
Table 58 : Qiagen: Company Snapshot
Table 59 : Qiagen: Financial Performance, FY 2022 and 2023
Table 60 : Qiagen: Product Portfolio
Table 61 : Qiagen: News/Key Developments, 2023
Table 62 : Revvity Inc.: Company Snapshot
Table 63 : Revvity Inc.: Financial Performance, FY 2022 and 2023
Table 64 : Revvity Inc.: Product Portfolio
Table 65 : Revvity Inc.: News/Key Developments, 2023 and 2024
Table 66 : Silence Therapeutics: Company Snapshot
Table 67 : Silence Therapeutics: Financial Performance, FY 2022 and 2023
Table 68 : Silence Therapeutics: News/Key Developments, 2022 and 2023
Table 69 : Sirnaomics: Company Snapshot
Table 70 : Sirnaomics: Financial Performance, FY 2022 and 2023
Table 71 : Sirnaomics: News/Key Developments, 2023
Table 72 : Sylentis S.A.: Company Snapshot
Table 73 : Sylentis S.A.: News/Key Developments, 2023
Table 74 : Switch Therapeutics: Company Snapshot
Table 75 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 76 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 77 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 78 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023

List of Figures

Summary Figure : Global Market for RNAi Technology, by Technology Type, 2021-2029
Figure 1 : RNAi Pathway
Figure 2 : Market Dynamics of RNAi Technology
Figure 3 : Tissues Targeted by RNAi Therapeutics
Figure 4 : Patents Documented Over Time, 2010-April 2024
Figure 5 : Global Market for RNAi Technology, by Technology Type, 2021-2029
Figure 6 : Global Market Shares of RNAi Technology, by Technology Type, 2023
Figure 7 : RNAi Therapeutics Timeline, 1998-2023
Figure 8 : Global Market for RNAi Therapeutics, by Region, 2021-2029
Figure 9 : Global Market for RNAi Therapeutics, by Therapeutic Area, 2021-2029
Figure 10 : Global Market for RNAi Therapeutics, by Delivery Method, 2021-2029
Figure 11 : MicroRNA (miRNA) Biomarkers in Various Cancers
Figure 12 : Global Market for RNAi Diagnostics, by Region, 2021-2029
Figure 13 : Global Market for RNAi Reagents and Tools, by Type, 2021-2029
Figure 14 : Global Market for RNAi Reagents and Tools, by Region, 2021-2029
Figure 15 : Global Market for RNAi Research Tools and Constructs, by Region, 2021-2029
Figure 16 : Global Market for RNAi Reagents, by Region, 2021-2029
Figure 17 : Global Market for RNAi Agriculture, by Region, 2021-2029
Figure 18 : Global Market for RNAi Technology, by Region, 2021-2029
Figure 19 : Global Market Shares of RNAi Technology, by Region, 2023
Figure 20 : Global Market Shares of RNAi Technology, by Suppliers/Manufacturers, 2023
Figure 21 : Research Communities' Key Sustainable Practices in Research Laboratories
Figure 22 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 23 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 24 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 25 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 26 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 27 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 28 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 29 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 30 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
Figure 31 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2023
Figure 32 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 33 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 34 : Revvity Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35 : Revvity Inc.: Revenue Share, by Country/Region, FY 2023
Figure 36 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023